Magnetic Group Signaling (MGS®) Technology

Magnetic Group Signaling (MGS®) standardizes NMR systems and sample processing to ensure reproducible results on different NMR instruments.

Learn more

One Sample -

All Answers

Advanced. Automated. Affordable. Mastering Metabolite Networks for Real-Time Precision Medicine.

Learn more

AXINON® System

AXINON® is the first modular software-based system providing hardware, operating system, MGS® processor and individual test applications.

Learn more

Nephrology. |Renal Function Assessment.


GFR — One of the most important markers for identifying impaired renal function

  • Chronic kidney disease (CKD) is a common consequence of many medical conditions, and it's prevalence is rising.​​​​
  • Hypertension and diabetes mellitus — two main CKD causes. 
  • Glomerular Filtration Rate (GFR) is one of the most common tests used, and included in all standard blood panels assessing kidney function. 

Currently, GFR is based on an estimation using clinical data and blood-based biomarkers, like creatinine or cystatin C. GFR can either be measured (mGFR) by tracer methods or estimated (eGFR).

mGFR methods are elaborate and time-consuming, and eGFR lacks accuracy in a number of common clinical situations. Because of this, clinical decision-making is difficult, especially early when intervention may help slow progression to end-stage renal disease.

1. 2011–2014 National Health and Nutrition Examination Survey and the CKD Epidemiology Collaboration (CKD-EPI) equation.

GFR testing. |With <i>AXINON<sup>&reg;</sup> GFR (NMR)</i>.

Advanced. Automated. Affordable.

Numares developed a novel multi-parametric serum test called AXINON®GFR(NMR) to assess kidney function and significantly improve on the current standard of serum creatinine-based estimated Glomerular Filtration Rate (eGFR).

Our NMR (nuclear magnetic resonance)-based early GFR data determination is more accurate than creatinine-based, conventional eGFR and comparable to tracer-based mGFR methods.

Using the metabolomics approach and Numares’ Magnetic Group Signaling (MGS®) technology, evaluating NMR-based GFR biomarkers yields defined metabolite constellations displaying impaired GFR.

AXINON® GFR(NMR) can improve patient care by offering an accurate, easy way to assess renal function, monitor disease progression and track therapies with nephrotoxic drugs.


FAQs

Technology. |The <i>AXINON<sup>&reg;</sup> IVD System</i>.

Easy. Fast. Efficient.

AXINON® System GFR(NMR) produces high-quality test results —  standardized NMR spectra based on our Magnetic Group Signaling (MGS®) technology.

MGS® with the AXINON® System allows for test-specific spectral analysis with highly reproducible results. 

  • Easy to use: One-step sample preparation with ready-to-use reagents. Requires minimal operator interaction. 
  • Efficient: Automated sample processing.

To date, more than 2 million tests have been performed worldwide, using the Numares technology.

Technology


* For Research Use only in the United States. numares’ products are not yet available for sale within the United States; they have not yet been approved or cleared by the U.S. Food and Drug Administration.

You did not activate the necessary cookies for this content.

activate necessary cookies and show content